Compare SCVL & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCVL | KMDA |
|---|---|---|
| Founded | 1978 | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 551.6M | 458.6M |
| IPO Year | 1994 | 2013 |
| Metric | SCVL | KMDA |
|---|---|---|
| Price | $18.26 | $8.48 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | ★ 286.3K | 64.8K |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.13% | 2.23% |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.57 | N/A |
| Revenue | ★ $1,202,885,000.00 | N/A |
| Revenue This Year | N/A | $14.79 |
| Revenue Next Year | N/A | $11.38 |
| P/E Ratio | ★ $12.18 | $24.59 |
| Revenue Growth | ★ 2.30 | N/A |
| 52 Week Low | $15.21 | $5.54 |
| 52 Week High | $26.54 | $9.35 |
| Indicator | SCVL | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 37.64 | 46.87 |
| Support Level | $16.79 | $6.69 |
| Resistance Level | $18.37 | $8.88 |
| Average True Range (ATR) | 0.86 | 0.25 |
| MACD | -0.26 | -0.07 |
| Stochastic Oscillator | 7.14 | 5.88 |
Shoe Carnival Inc is a family footwear retailer that offers a broad assortment of dress, casual, and athletic footwear for men, women, and children with an emphasis on national name brands such as Nike, Skechers, Adidas, Puma, HEYDUDE, Converse, Vans, and Crocs. The company operates its business as one reportable segment based on the similar nature of products sold; merchandising, distribution, and marketing processes involved; target customers; and economic characteristics of stores and e-commerce platforms. Its bricks-first, omnichannel approach provides customers easy access to a wide assortment of branded footwear for work, athletics, daily activities, and special events via a choice of delivery channels.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.